- Home
- LVLU vs TXMD Comparison
LVLU vs TXMD Comparison
Compare LVLU & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- TXMD
- Stock Information
- Founded
- LVLU 1996
- TXMD 2008
- Country
- LVLU United States
- TXMD United States
- Employees
- LVLU N/A
- TXMD N/A
- Industry
- LVLU Catalog/Specialty Distribution
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- TXMD Health Care
- Exchange
- LVLU Nasdaq
- TXMD Nasdaq
- Market Cap
- LVLU 11.3M
- TXMD 12.7M
- IPO Year
- LVLU 2021
- TXMD N/A
- Fundamental
- Price
- LVLU $4.50
- TXMD $1.07
- Analyst Decision
- LVLU Hold
- TXMD
- Analyst Count
- LVLU 1
- TXMD 0
- Target Price
- LVLU $15.00
- TXMD N/A
- AVG Volume (30 Days)
- LVLU 168.7K
- TXMD 16.9K
- Earning Date
- LVLU 11-12-2025
- TXMD 11-11-2025
- Dividend Yield
- LVLU N/A
- TXMD N/A
- EPS Growth
- LVLU N/A
- TXMD N/A
- EPS
- LVLU N/A
- TXMD N/A
- Revenue
- LVLU $292,337,000.00
- TXMD $2,559,000.00
- Revenue This Year
- LVLU N/A
- TXMD $427.09
- Revenue Next Year
- LVLU $2.53
- TXMD N/A
- P/E Ratio
- LVLU N/A
- TXMD N/A
- Revenue Growth
- LVLU N/A
- TXMD 156.93
- 52 Week Low
- LVLU $2.98
- TXMD $0.70
- 52 Week High
- LVLU $28.05
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- LVLU 52.83
- TXMD 42.49
- Support Level
- LVLU N/A
- TXMD $1.06
- Resistance Level
- LVLU $4.79
- TXMD $1.14
- Average True Range (ATR)
- LVLU 0.48
- TXMD 0.05
- MACD
- LVLU -0.10
- TXMD 0.00
- Stochastic Oscillator
- LVLU 84.11
- TXMD 11.05
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.